Brief: Moberg Pharma Reports Qtrly Diluted Earnings Per Share SEK 0.62

Moberg Pharma AB (publ)

12/02/2019 24:40

Feb 11 (Reuters) - Moberg Pharma Ab (Publ)  MBPH.ST :
    * MOBERG PHARMA AB YEAR-END REPORT 2018
    * SAYS  FULL YEAR 2018 NET REVENUE SEK 439.0 MILLION
    * QTRLY DILUTED EARNINGS PER SHARE SEK 0.62
    * SAYS BOARD OF DIRECTORS PROPOSES THAT NO DIVIDEND BE PAID
FOR
2018
    * MOBERG PHARMA AB  - QTRLY NET REVENUE SEK 97.1 MILLION
    * Q4 REVENUE VIEW SEK 90.0 MILLION -- REFINITIV IBES DATA
    * Q4 EARNINGS PER SHARE VIEW SEK 0.45 -- REFINITIV IBES DATA
    * FY2018 REVENUE VIEW SEK 432.0 MILLION -- REFINITIV IBES
DATA
    * FY2018 EARNINGS PER SHARE VIEW SEK 0.96 -- REFINITIV IBES
DATA
    * SAYS SIGNED A LICENSE AGREEMENT WITH BAYER AG TO
COMMERCIALIZE
MOB-015 IN EUROPE
    * QTRLY U.S. SALES WERE STRONG , CONTRIBUTING TO
DOUBLE-DIGIT
GROWTH FOR FULL YEAR
    * SAYS MOBERG PHARMA IS ELIGIBLE TO RECEIVE MILESTONES
PAYMENTS UP
TO EUR 50 MILLION FROM  AGREEMENT WITH BAYER AG
    * Q4 NET REVENUE SEK 97.1 MILLION
    * SAYS  Q4 OPERATING CASH FLOW PER SHARE SEK 0.95 (1.68)
    * SAYS  FULL YEAR 2018 DILUTED EARNINGS PER SHARE SEK 1.14
(0.64)
    * MOBERG - IN BEGINNING OF 2019, SCREENING OF PATIENTS TO
EUROPEAN
PHASE 3 STUDY FOR MOB-015 FINALIZED ;EXPECT RANDOMIZATION TO BE
COMPLETED DURING Q1
    * MOBERG PHARMA-CAN EXPECT TOPLINE RESULTS FOR MOB-015 U.S.
PHASE
3 STUDY  IN LATE 2019,CORRESPONDING RESULTS FROM EUROPEAN PHASE
3 STUDY IN Q2 OF 2020

Source text for Eikon:  ID:nWkr9MxVKK 
Further company coverage:  MBPH.ST 

 ((Reuters.Briefs@thomsonreuters.com;))